Key points are not available for this paper at this time.
The synthesis and characterization of ruthenium(II)-arene triarylphosphine complexes, Ru(η 6 - p -cymene)(PAr 3 )(NCCH 3 )ClPF 6 , where Ar = (3,5- t Bu 2 C 6 H 3 -) ( L1 ), (3,5-Me 2 C 6 H 3 -) ( L2 ), (4-MeO-3,5-Me 2 C 6 H 2 -) ( L3) and (4-MeOC 6 H 4 -) ( L4 ), are described. The structures have been confirmed by IR and 31 P NMR spectroscopy and by single crystal X ray diffraction studies. The redox behavior of the complexes has been investigated by voltammetry in CH 3 CN, with stability over a wide potential window ΔE ≅ 2.7 V. The antibacterial properties of the complexes have been studied against a Gram-positive and a Gram-negative strain. Complex 2 exhibits strong activity against S. aureus (MIC 25 µmol L -1 , IC 50 13.5 µmol L -1 ) and notably potent activity against MRSA (MIC 12.5 µmol L -1 , IC 50 8.52 µmol L -1 ). Complex 3 also demonstrates activity against S. aureus (MIC 25 µmol L -1 , IC 50 15.9 µmol L -1 ) and MRSA (IC 50 11.04 µmol L -1 ), though its MIC against MRSA is >100 µmol L -1 . By contrast, complex 4 is inactive. The interactions of 2 and 4 with phospholipid monolayers were investigated by the Langmuir monolayer method, in a system that simulates the Staphylococcus aureus cell membrane. Complex 2 interacts with and disrupts the organization of these monolayers, and this result possibly indicates that cell membrane rupture causes the antibacterial effect.
Rutka et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: